These disturbances, compounded by impaired mitochondrial fatty acid oxidation, ultimately contribute to dyslipidemiacharacterized by elevated serum triglycerides, LDL cholesterol (LDL-C), and total cholesterolwhich accelerates pathological processes such as atherosclerosis and fatty liver disease [119, 120]
Metformin primarily reduces glucose production in the liver and increases insulin sensitivity
Semaglutide reveals both peptides unique characteristics
In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape
Moreover, melatonin has been shown to reduce ferroptosis in various diseases affecting multiple organs, suggesting its potential as a therapeutic agent for ferroptosis-associated conditions [38, 39]
![Top asymétrique en dentelle à fines bretelles [MARRON]](https://cdn.shopify.com/s/files/1/0528/7238/0576/files/462AE418-3513-454D-9FF8-BE31D5131E19.jpg?v=1776531250)